Brean Murray Ugprades Adolor Corp. (ADLR) to Buy
More News related to ADLR
- After-Hours Movers 6/3: CYBX, CMTL, PSS Higher; MATK, ADLR, HOTT Lower
- Adolor (ADLR) to Cut Headcount by 45 Employees, or 28% of Workforce
- Adolor Corporation Announces Staff Reductions and Restructuring
- Adolor (ADLR) Misses Q1 View By 3c
- Adolor (ADLR) Reports Q4 Loss of $0.33, Misses by 3c
Brean Murray ugprades Adolor Corp. (Nasdaq: ADLR) from Hold to Buy with a $6 price target, citing valuation.
The firm said, "Adolor shares have depreciated 50% from their annual high. With the stock currently trading below cash (market cap of $141 million and 2Q08 cash position of $161 million), we believe investors are completely overlooking the company's assets, including Entereg in the already approved POI indication, Entereg in its Phase 3-ready stage of clinical development for chronic opioid bowel dysfunction (OBD), the delta opioid agonist program in collaboration with Pfizer (one in Phase 2a and one in Phase 1), as well as the company's preclinical drug candidates, most notably other mu opioid receptor antagonists."
Related Categories
UpgradesStocks Mentioned
-0.06Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
